Becton Dickinson

Becton Dickinson and Euroclone aim to develop and commercialize the molecular assays for launch outside the US in 2018, and in the US at a later date.

The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.

The company missed analyst estimates on its top line, but beat analyst estimates for adjusted earnings per share and raised its adjusted EPS guidance for FY 2017.

The company's new FACSLyric flow cytometer system is for use with BD Multitest assays for assessing suspected immunological deficiencies in patients.

Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.

The firm said that the test, which detects infectious diarrhea caused by harmful intestinal bacteria, extends the BD MAX Enteric Panel Portfolio. 

The offering of $2.25 billion of common stock was priced at $176.50 per share, while the offering of $2.25 billion in depositary shares was priced at $50 per share.